Magenta Therapeutics Announces New Clinical Data on its Lead Expansion Clinical Program, MGTA-456, Presented at American Society of Gene and Cell Therapy Annual Meeting

CAMBRIDGE, Mass.--()--Magenta Therapeutics, a biotechnology company developing therapies to improve and expand the use of curative blood stem cell transplantation for more patients, today announced the presentation of new clinical data on its lead expansion program, MGTA-456, at the American Society of Gene and Cell Therapy (ASCGT) Annual Meeting in Washington, D.C.

The presentation by John E. Wagner, M.D., executive medical director of the Bone Marrow Transplantation Program at the University of Minnesota, highlights results from three clinical trials involving a total of 36 patients, which evaluated the use of MGTA-456 to expand the number of umbilical cord blood stem cells in a variety of transplant settings, including single cord transplant in older patients undergoing non-myeloablative conditioning.

The presentation, Hematopoetic Stem Cell Expansion with Stem Regenin-1, will begin at 8:35 am in the Thurgood Marshall East room at the Marriott Wardman Park Hotel. The abstract is available online at: http://www.abstractsonline.com/pp8/#!/4399/presentation/927

About MGTA-456

MGTA-456 (formerly HSC835), aims to expand the number of cord blood stem cells used in transplants to achieve superior clinical outcomes compared to standard transplant procedures, and to enable more patients to benefit from a transplant. Early results published in Science1 demonstrated the ability of MGTA-456 to significantly increase the number of umbilical cord blood stem cells. Clinical results reported in Cell Stem Cell2 demonstrated that this approach yielded an increased expansion of stem cells. Magenta is developing MGTA-456 in multiple diseases, including immune and blood diseases.

About Magenta Therapeutics

Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated, but modular approach to stem cell therapies to create patient benefits. Founded by internationally recognized leaders in stem cell transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.magentatx.com.

1 Science. 2010 Sep 10;329(5997):1345-8.
2 Cell Stem Cell. 2016 Jan 7;18(1):144-55

Contacts

Ten Bridge Communications
Dan Quinn, 781-475-7974
dan@tenbridgecommunications.com

Release Summary

Magenta Therapeutics today announced the presentation of new clinical data on its lead expansion program, MGTA-456, at the American Society of Gene and Cell Therapy (ASCGT) Annual Meeting.

Contacts

Ten Bridge Communications
Dan Quinn, 781-475-7974
dan@tenbridgecommunications.com